RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$6.66
+0.56 (+9.18%)
Financial Highlights (FY 2025)
Revenue
81.98M
Net Income
12.35M
Gross Margin
28.8%
Profit Margin
15.1%
Rev Growth
+24.2%
D/E Ratio
0.79
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 28.8% | 28.8% | 28.8% |
| Operating Margin | 13.1% | 15.9% | 13.5% |
| Profit Margin | 15.1% | 14.3% | 16.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Gross Profit | 23.57M | 24.39M | 19.80M |
| Operating Income | 10.74M | 13.50M | 9.32M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Gross Margin | 28.8% | 28.8% | 28.8% |
| Operating Margin | 13.1% | 15.9% | 13.5% |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| Rev Growth | +24.2% | +0.2% | +22.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 97.84M | 116.11M | 118.62M |
| Total Equity | 123.72M | 117.70M | 119.20M |
| D/E Ratio | 0.79 | 0.99 | 1.00 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |